Table 2.

Response rates in mDLC patients treated with neoadjuvant therapy compared to IDC and ILC.

Neoadjuvant chemotherapy
	mDLC (N = 17)	ILC (N = 57)	p value	IDC (N = 180)	p value
Volume reduction (%)	78.5 (62.38, 92.5)	76 (26.5, 90.5)	0.22	75 (40.75, 95.62)	0.29
BCS attempted
Yes	9 (53%)	19 (33%)	0.16	70 (39%)	0.34
No	8 (47%)	38 (67%)		110 (61%)
Rate of successful BCS
Yes	5 (56%)	6 (32%)	0.41	49 (70%)	0.45
No	4 (44%)	13 (68%)		21 (30%)
pCR
Yes	3 (18%)	4 (7%)	0.34	24 (13%)	0.71
No	14 (82%)	52 (93%)		156 (87%)
Neoadjuvant endocrine therapy
Rate of successful BCS	mDLC (N = 7)	ILC (N = 21)	p value	IDC (N = 37)	p value
Yes	2 (40%)	6 (60%)	0.61	14 (67%)	0.34
No	3 (60%)	4 (40%)		7 (33%)
pCR
Yes	0 (0%)	0 (0%)		0 (0%)
No	7 (100%)	21 (100%)		37 (100%)

Volume reduction is presented as a percentage. Median (interquartile) is shown for volume reduction and frequency (%) is shown for other categorical variables.

BCS breast-conserving surgery, pCR pathologic complete response.